ABSTRACf. Paired sera from 30 patients with mucocutaneous lymph node syndrome (Kawasaki disease) were studied for possible effects on human vascular endothelial cells growth in vitro. The majority of sera from acute phase muco-cutaneous lymph node syndrome patients significantly enhanced endothelial cell proliferation more than those from convalescent phase patients, infectious diseases patients, and age-matched normal controls. This stimulation was considered to be specific for EC since mucocutaneous lymph node syndrome sera did not enhance fibroblast growth more than normal sera. Fractionation of the serum with gel filtration failed to clearly detect the molecular properties of this effect, although both heavy and light material possessed this activity. Extensive search for circulating immune complex in muco-cutaneous lymph node syndrome sera were negative, suggesting that the enhanced endothelial cell proliferation was due to serum components other than immune complexes. (Pediatr Res 20:943-946, 1986) Received October 4,1985 ; accepted May 14, 1986 . Correspondence Dr. Yoshimi Hashimoto, Department ofInternal Medicine and Physical Therapy, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyoku. Tokyo, Japan.
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Kawasaki disease (MCLS) is an acute febrile disease of infants first reported in Japan in 1967 (I). Since then, many studies have described the clinical manifestations of this disease, and it is now accepted that MCLS is a systemic vasculitis associated with coronary artery involvement which occasionally leads to death fatality (2) . Pathological studies of fatal MCLS cases revealed the presence ofsystemic vasculitis/arteritis, predominately in the coronary arteries (3) (4) (5) . The etiology ofMCLS is unknown. In the present study we have demonstrated the presence of a stimulating effect of MCLS sera on EC growth/proliferation in 944 HASHIMOTO ET AL.
Biological Co., Grand Island, NY). EC were thus grown on the plastic surface of the culture flask (Coming cat. no. 25100).
All endothelial cells used in this study were identified by detecting factor VIII antigen with indirect immunofluorescence technique as described previously (7, 8) . Smooth muscle cells and fibroblasts, possible contaminating cell types, have different morphological characteristics from EC and contamination of monocytes was easily eliminated by extensively washing the intact lumen of the umbilical vein.
Fibroblasts. Human skin fibroblasts were primarily obtained from the forearm of a normal donor and cultured in RPMI-1640, containing 10% FCS, penicillin, and streptomycin. After 2-3 wk at 37" C with 5%C0 2 , the cell layer was detached with 0.1 % trypsin and 0.02% EDTA, and transferred to 25 cm 2 culture flask for continuous culture.
EC proliferation assay. This was done using second to third passaged cells according to the method of Kahaleh et al. (9) . Ten thousand viable endothelial cells in RPMI-I640 medium with 2% FCS were seeded in triplicate wells of Falcon flat bottom microtest plates and left overnight. The medium was then replaced with RPMI medium supplemented with 20% test serum or test drug. After 48 h incubation, 3H-TdR was introduced at I JICi/ml concentration. Twenty-four hours laters, the medium was replaced with 0.05% trypsin-Om % EDTA in PBS. Then the cells were harvested on glass-fiber filters and counted in a scintillation counter. The same assay was performed using skin fibroblasts.
Immune complex assays. Three radioimmunoassays to detect immune complexes were performed as previously described (10) (11) (12) (13) . Briefly, the Clq-solid phase (Clq-SP) and the monoclonal rheumatoid factor-solid phase (mRF-SP) assays were performed by coating polystylene tubes with 0.5 ml isolated Clq (5 JIg/ml) or mRF (85 JIg/ml) for 16 h at 4 0 C. Remaining binding sites were blocked with 1% of bovine serum albumin in PBS contain--ing 1'0 mM-EDTA (5 mM sodium phosphate, 0.15 M sodium chloride, 10 mM EDTA, pH 8.0) (BSA-PBSE). Test samples (0.005 ml) were added to the coated tubes and BSA-PBSE (0.495 ml) was added to bring the final volume up to 0.5 ml. After incubation for 16 h at 4 0 C, the tubes were washed three times with 2 ml of PBSE, and immune complexes bound to Clq or mRF were measured using a specific I'25_F(ab')2 rabbit antihuman Fab. The results of both solid phase assays were recorded as ng of F(ab')2 rabbit antihuman Fab bound per tube. The sensitivity and specificity of each of these assays were identical to previous reports (11 -13) .
The red blood cell assays were performed with a 4% suspension of normal human red blood cells (type 0) in GVB (0.1 % gelatin, 0.15 M barbiturate, pH 7.4, containing Ca++ and Mg++) (GVB). One volume of this suspension was mixed with one volume of one-fourth diluted normal human serum as a complement source and one volume of heat-inactivated test serum (non-diluted). After incubation for IS min at 37" C, the red blood cells were washed three times with GVB and resuspended in GVB at 4%. Fifty JIl of this suspension was incubated with 50 JIl of 1'25_ antihuman IgG (Hoechst Japan Co., Tokyo, Japan) for I h at 37" C. After washing, the cells were counted and the results were recorded as amount of heat aggregated IgG equivalent, as reported previously (13) . RESULTS 
EC proliferation assay.
We measured the 3H-TdR uptake of the cultured vascular EC after incubation in 20% test or control sera. We first determined EC proliferation by 18 normal sera and found no significant differences among these sera. Proliferative activity of EC, however, showed considerable variation using individual umbilical cord samples even with identical normal serum. Therefore, the results of the EC proliferation assays were expressed as an index (PI) instead of actual cpm. Six normal sera were used in one experiment and the mean cpm of these sera were designated as 1.00; PI was then calculated by dividing each individual value by this mean. Figure I summarizes the results of the EC proliferation assay.
The proliferation indices were 1.00 ± 0.02 (SD) for normal children (n = 19), 1.32 ± 0.32 for infectious diseases patients (n = 14), and 1.88 ± 1.29 for acute phase MCLS patients. Both the indices in infectious diseases patients and MCLS patients were significantly higher than in normal children (p < 0.00 I by MannWhitney V test). The index in MCLS patients was, furthermore,-significantly higher than in infectious diseases patients (p < 0.005). Figure 2 shows the result of an experiment in which six paired (both first and second) sera from six MCLS patients were tested for EC proliferation activity along with sera from six normal children. The mean cpm with the first MCLS serum (16,810 ± 3,209) was significantly higher than those for both the second serum (9,389 ± 2,692) and the normal serum (11,936 ± 2,297). There was no difference between the second serum and the normal serum. In each case for the six MCLS patients, the first serum stimulated EC proliferation more than the second serum.
To see ifthis enhanced proliferation by MCLS sera was specific to EC, both EC and fibroblasts proliferation assays were done simultaneously. The result as shown in Table I indicates EC proliferation with MCLS sera was significantly higher than that with NHS, whereas no significant difference was observed _ between MCLS and NHS for the fibroblast proliferation.
In the next experiment, we fractionated the serum with Sephadex G-200 Gel filtration in an attempt to detect the molecular property of the activity observed in MCLS patients. Both the patient's and normal serum were applied to the column and each pooled fraction was concentrated to the initial serum volume and tested for EC proliferation potency. In Figure 3 , cpm with each pooled fraction were plotted for both normal child serum (solid circles) and active MCLS serum (open circles). The EC donor was different in the two experiments, which explains the considerable difference of background growth. In the case of normal serum, no single fraction stimulates EC to proliferation except small peaks around both IgG and albumin fractions. In sera of active MCLS, considerable activity was observed both in the void volume and in the IgG peaks; weak activity was noted in small molecular fraction.
Immune complex assays. Since several investigators reported the presence of circulating immune complexes in MCLS sera, we further investigated the possible presence of immune complexes and its association to EC proliferation activity. 
DISCUSSION
In the present study, we investigated the possible effects of MCLS sera on human vascular EC proliferation in vitro. The results obtained suggest that acute phase MCLS sera have a potent activity which accelerates EC proliferation in vitro, whereas this is not present in convalescent MCLS sera or sera from normal children. This effect was considered specific for EC since acute MCLS sera did not enhance proliferation of fibroblasts. Sera from infectious diseases patients also possessed stimulatory activity but to a lesser degree than that of acute MCLS patients. This activity is probably not due to drugs administered to the patients, since these agents had no effect on EC proliferation in vitro (Table 2 ). An attempt to analyze this activity on column fractionation did not clearly elucidate its molecular nature, although both large molecular weight and small molecular weight substances had activity.
Circulating immune complexes have been implicated in the pathogenesis of MCLS but the results are conflicting (14) (15) (16) (17) (18) . We, therefore, reassessed the presence of immune complexes using multiple assays simultaneously. The assay utilizing Clq for those assays. Abnormal values (values beyond the mean + 2 SD of normal control) were observed in one patient (3.3%) with Clq-SP, one (3.3%) with mRF-SP, and six (20%) with red cell assays. However, no significant difference was detected between the mean level of immune complexes of normal controls and MCLS in the three methods tested. Furthermore, no significant correlation was observed between the EC PI and the immune complex level in each patient (data not shown).
Finally, we studied the possible effect of drugs administered; prednisolone and aspirin were the main drugs. As indicated in Table 2 , prednisolone suppressed EC proliferation in a dosedependent manner, whereas aspirin had little effect on EC proliferation within the concentrations tested. sooo cpm x 10-1 detects complement fixing immune complexes, the mRF assay detects both complement-fixing and noncomplement fixing immune complexes (10) (11) (12) , and the red cell assay detects C3-bound complexes (13) . Our results strongly suggest that patients with this disease do not possess significant levels of circulating immune complexes. Further, no association was observed between the EC PI and immune complex levels (data not shown). These observations indicate that circulating immune complexes do not playa major role in the enhanced EC proliferation.
"Acute phase reactants," present in the sera of infectious diseases patients may play some role. One possibility is that acute MCLS serum contains larger amount of acute phase reactants. Platelet-derived factor (19) (20) (21) , endotoxin (22) (23) , and interleukin I-like material (24) which are reported to stimulate EC growth may be candidates and these factors are now under investigation.
The role of the activity demonstrated in the present study on the in vivo vascular damage observed in MCLS is not yet known. Panarteritis followed by aneurysm formation is the hallmark of vascular involvement of MCLS. Endothelial cells are reported to produce both prostacydin (25) and platelet-activating factor (26) which may modify inflammatory process via platelet function. Stimulation of EC may enhance the production of plateletactivating factor (26) , which amplifies the acute inflammatory process and thrombogenesis.
